{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T06:09:08Z","timestamp":1768630148155,"version":"3.49.0"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009647","name":"University Grants Commission- Nepal","doi-asserted-by":"publisher","award":["Ph.D.\/74-75\/S&T-17"],"award-info":[{"award-number":["Ph.D.\/74-75\/S&T-17"]}],"id":[{"id":"10.13039\/501100009647","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The lymphatic filariasis (LF) elimination program in Nepal was launched in 2003, three years after the implementation of a global program to eliminate lymphatic filariasis globally. Based on antigenic prevalence below the cut-off value, i.e.,\u2009\u2264\u20092% shown by the transmission assessment survey (TASI) report of 2017\u20132018, the program was stopped in Nepal. The report indicated that antigen-positive children were clustered in the community and considered hotspots. In order to find the status of lymphatic filariasis transmission at the community level, the present study was designed in the hotspots to assess antigenemia among the children born after mass drug administration (MDA), along with vector infection\/infectivity in identified hotspots of Central Nepal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Each of two districts from the hilly and Terai regions of Central Nepal was selected based on comparatively high antigenic prevalence shown by previous TASI reports, and a descriptive cross-sectional study was designed. Two specific methods were employed: a Filarial Test Strip (Alere, Scorborough, ME) was used for antigenemia (n\u2009=\u2009791) among children, and gravid traps were used for vector mosquito collection. Parous mosquitoes (n\u2009=\u20093344) were dissected for infection\/or infectivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The result indicated that antigen-positive cases were unexpectedly increased in hotspots of one each from the hilly region (Dhading) and Terai region (Mahottari), i.e., above the critical level (\u2265 2%). Antigen prevalence increased from baseline prevalence, which was significantly associated with the number of MDA rounds but not with MDA coverage. The upper confidence limit of antigenemia and Mf infection was above the critical cut-off value in hotspots of all selected endemic districts. However, none of the vector mosquitoes, such as\n                      <jats:italic>Culex quinquefasciatus,<\/jats:italic>\n                      was found to be infected with any larval stage of filarial nematode.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The result showed an increase in antigenemia and Mf prevalence in high baseline prevalence areas with fewer MDA rounds. Lack of correlation between filarial infection in humans and xenomonitoring could be low sensitivity of xenomonitoring by microscopy. TAS-based assessment of antigenemia in children for stopping MDA can be supplemented with molecular xenomonitoring in hotspots.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0338141","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T18:35:12Z","timestamp":1768588512000},"page":"e0338141","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transmission status of lymphatic filariasis in hotspots of filarial infection, persistent districts of nepal during post-MDA surveillance"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9423-1552","authenticated-orcid":true,"given":"Pramod Kumar","family":"Mehta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahendra","family":"Maharjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"pone.0338141.ref001","unstructured":"WHO. Lymphatic filariasis: a handbook of practical entomology for national lymphatic filariasis elimination programs. 2013. https:\/\/www.who.int\/publications\/i\/item\/9789241505642"},{"issue":"3","key":"pone.0338141.ref002","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1089\/lrb.2013.0021","article-title":"Insights into the pathogenesis of disease in human Lymphatic Filariasis","volume":"11","author":"TB Nutman","year":"2013","journal-title":"Lymphatic Research and Biology"},{"issue":"9","key":"pone.0338141.ref003","article-title":"The global distribution of lymphatic filariasis, 2000-18: a geospatial analysis","volume":"8","author":"Local Burden of Disease 2019 Neglected Tropical Diseases Collaborators","year":"2020","journal-title":"Lancet Glob Health"},{"key":"pone.0338141.ref004","unstructured":"WHO. Lymphatic filariasis. 2023. [Cited 2024 March 16]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lymphatic-filariasis"},{"issue":"40","key":"pone.0338141.ref005","first-page":"565","article-title":"Global program to eliminate lymphatic filariasis: progress report","volume":"99","author":"WHO","year":"2024","journal-title":"Weekly Epidemiological Record"},{"key":"pone.0338141.ref006","unstructured":"WHO. Lymphatic Filariasis\u2013Key Facts. 2024. [Cited 2024 November]. https:\/\/www.who.int\/news--room\/factsheets\/detail\/lymphatic-filariasis"},{"key":"pone.0338141.ref007","volume-title":"Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021\u20132030","author":"WHO","year":"2020"},{"issue":"10258","key":"pone.0338141.ref008","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"T Vos","year":"2020","journal-title":"The Lancet"},{"key":"pone.0338141.ref009","volume-title":"Towards eliminating lymphatic filariasis: progress in the South-East Asia region","author":"WHO","year":"2013"},{"issue":"1","key":"pone.0338141.ref010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011932","article-title":"Assessment of microfilaremia in \u201chotspots\u201d of four lymphatic filariasis endemic districts of Nepal during post-MDA surveillance","volume":"18","author":"PK Mehta","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"pone.0338141.ref011","article-title":"Impact of mass drug administration for elimination of lymphatic filariasis in Nepal","volume":"11","author":"CR Ojha","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"pone.0338141.ref012","volume-title":"Annual report 2017\u20132018","author":"Department of Health Services"},{"key":"pone.0338141.ref013","unstructured":"Department of Urban Development and Construction. [Cited 25 March 2024]. http:\/\/www.dudbc.gov.np"},{"key":"pone.0338141.ref014","unstructured":"WHO. The role of polymerase chain reaction techniques for assessing lymphatic filariasis transmission. 2009. [Cited 21 March 2024]. https:\/\/www.who.int\/publications\/i\/item\/WHO-HTM-NTD-PCT-2009.1"},{"issue":"1","key":"pone.0338141.ref015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/trstmh\/trs001","article-title":"Evaluation of gravid traps for the collection of Culex quinquefasciatus, a vector of lymphatic filariasis in Tanzania","volume":"107","author":"SR Irish","year":"2013","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"7","key":"pone.0338141.ref016","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.pt.2009.03.013","article-title":"The role of monitoring mosquito infection in the Global Programme to Eliminate Lymphatic Filariasis","volume":"25","author":"EM Pedersen","year":"2009","journal-title":"Trends Parasitol"},{"key":"pone.0338141.ref017","volume-title":"Alternative mass drug administration regimens to eliminate lymphatic filariasis","author":"Guideline","year":"2017"},{"issue":"4","key":"pone.0338141.ref018","first-page":"313","article-title":"Strengthening of mass drug administration implementation is required to eliminate lymphatic filariasis from India: an evaluation study","volume":"45","author":"C Lahariya","year":"2008","journal-title":"J Vector Borne Dis"},{"issue":"4","key":"pone.0338141.ref019","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1473-3099(04)00973-9","article-title":"Mathematical modelling and the control of lymphatic filariasis","volume":"4","author":"E Michael","year":"2004","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"pone.0338141.ref020","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1017\/S0950268899003702","article-title":"EPIFIL: the development of an age-structured model for describing the transmission dynamics and control of lymphatic filariasis","volume":"124","author":"RA Norman","year":"2000","journal-title":"Epidemiol Infect"},{"issue":"7","key":"pone.0338141.ref021","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0169-4758(00)01691-4","article-title":"Effectiveness of annual ivermectin treatment for Wuchereria bancrofti infection","volume":"16","author":"AP Plaisier","year":"2000","journal-title":"Parasitol Today"},{"issue":"11","key":"pone.0338141.ref022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005027","article-title":"Improving coverage and compliance in mass drug administration for the elimination of LF in Two \u201cEndgame\u201d Districts in Indonesia using micronarrative surveys","volume":"10","author":"A Krentel","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"pone.0338141.ref023","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13071-016-1311-1","article-title":"Compliance with anthelmintic treatment in the neglected tropical diseases control programmes: a systematic review","volume":"9","author":"KV Shuford","year":"2016","journal-title":"Parasit Vectors"},{"key":"pone.0338141.ref024","author":"B Bartilol","year":"2024","journal-title":"Xenomonitoring of Lymphatic filariasis and risk factors for transmission on the Kenyan coast. Cold Spring Harbor Laboratory"},{"issue":"12","key":"pone.0338141.ref025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278655","article-title":"Integrated survey of helminthic neglected tropical diseases and comparison of two mosquito sampling methods for lymphatic filariasis molecular xenomonitoring in the River Galana area, Kilifi County, coastal Kenya","volume":"17","author":"SM Njenga","year":"2022","journal-title":"PLoS One"},{"issue":"19","key":"pone.0338141.ref026","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1706854","article-title":"A Trial of a triple-drug treatment for Lymphatic Filariasis","volume":"379","author":"CL King","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"pone.0338141.ref027","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1056\/NEJMc1914262","article-title":"Single-Dose Triple-Drug Therapy for Wuchereria bancrofti - 5-Year Follow-up","volume":"382","author":"CL King","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0338141.ref028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009294","article-title":"An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia","volume":"15","author":"T Supali","year":"2021","journal-title":"PLoS Negl Trop Dis"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0338141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T18:35:25Z","timestamp":1768588525000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0338141"}},"subtitle":[],"editor":[{"given":"Kenneth Bentum","family":"Otabil","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0338141","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]}}}